Multiple roles of the prostaglandin D₂ signaling pathway in reproduction

Moïra Rossitto, Safdar Ujjan, Francis Poulat and Brigitte Boizet-Bonhoure

Genetic and Development Department, Institute of Human Genetics, CNRS UPR1142,
34094 Montpellier Cedex 05, France

Correspondence should be addressed to B Boizet-Bonhoure; Email: brigitte.boizet@igh.cnrs.fr

Abstract

Prostaglandins signaling molecules are involved in numerous physiological processes. They are produced by several enzyme-limited reactions upon fatty acids, which are catalyzed by two cyclooxygenases and prostaglandin synthases. In particular, the prostaglandins E₂ (PGE₂), D₂ (PGD₂), and F₂ (PGF_{2α}) have been shown to be involved in female reproductive mechanisms. Furthermore, widespread expression of lipocalin- and hematopoietic-PGD₂ synthases in the male reproductive tract supports the purported roles of PGD₂ in the development of both embryonic and adult testes, sperm maturation, and spermatogenesis. In this review, we summarize the putative roles of PGD₂ signaling and the roles of both PGD₂ synthases in testicular formation and function. We review the data reporting the involvement of PGD₂ signaling in the differentiation of Sertoli and germ cells of the embryonic testis. Furthermore, we discuss the roles of lipocalin-PGD₂ synthase in steroidogenesis and spermatogenesis, in terms of lipid molecule transport and PGD₂ production. Finally, we discuss the hypothesis that PGD₂ signaling may be affected in certain reproductive diseases, such as infertility, cryptorchidism, and testicular cancer.

Reproduction (2015) **149** R49–R58

Introduction

Prostaglandins (PGs) derived from polyunsaturated fatty acids belong to the superfamily of eicosanoids. The eicosanoid cascade starts with the activation of phospholipases A₂ and C that release arachidonic acid from the cellular membrane. Arachidonic acid is oxidized and then reduced by the enzymes cyclooxygenases 1 and 2 (COX1 and COX2, also referred to as prostaglandin endoperoxidase H synthase 1 and 2 (PTGS1 and PTGS2)), to be converted into PGG₂ and PGH₂. The COXs are key enzymes in PG biosynthesis and differ in their expression levels and tissue distribution; COX1 is constitutively expressed, whereas expression of COX2 is induced (Simmons *et al.* 2004). PGH₂, the unstable reaction intermediate, is then converted into either PGD₂, PGE₂, PGF_{2α} or prostacyclin (PGI₂) and thromboxane A₂ (TxA₂), by the action of specific terminal PG synthases: prostaglandin D synthase (PGDS), prostaglandin E synthase (PGES), prostaglandin F synthase (PGFS) or prostacyclin synthase (PGIS), or thromboxane synthase (TXS) respectively (Fig. 1 and Table 1) (Cha *et al.* 2006). PGs are rapidly inactivated by oxidation by the NAD⁺-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) (Fincham & Camp 1983). PGs are involved in the cardiovascular, gastrointestinal, genitourinary, endocrine, respiratory,

immune, and nervous systems (Hata & Breyer 2004). These molecules act locally in an autocrine and/or paracrine manner and their actions are complex, not least because, given the structural similarity of these molecules and their receptors, PGs may have synergistic or antagonistic effects upon the same physiological processes (Woodward *et al.* 2011, Tootle 2013).

PGD₂ is actively produced in many organs, and is the most abundant prostanoid in the CNS (Urade & Hayaishi 2000a) and in the respiratory tract and airways of asthmatic patients (Oguma *et al.* 2008). PGD₂ has essential roles in various physiological processes (Matsuoka *et al.* 2000, Kobayashi & Narumiya 2002, Qu *et al.* 2006, Huang *et al.* 2007, Taniguchi *et al.* 2007, Oguma *et al.* 2008, Gao *et al.* 2009, Nieves & Garza 2014), and particularly in several steps of the reproduction function (this function will be discussed further in the following paragraphs). Also, PGD₂ together with the prostaglandins PGE₂ and PGI₂, in conjunction with other mediators such as histamine, are involved in the inflammation process (Hata & Breyer 2004, Herlong & Scott 2006). Hematopoietic PGDS (H-PGDS) is the key enzyme in the synthesis of PGD₂ in the immune system and mast cells (Urade & Hayaishi 2000a, Kanaoka & Urade 2003). Furthermore, the resolution of inflammation is accompanied by a shift from the biosynthesis

Figure 1 Pathway of prostanoid biosynthesis and signaling. Arachidonic acid is metabolized by the action of cyclooxygenase (COX) first to prostaglandin endoperoxide (PGG₂) and then to PGH₂, which is subsequently converted to various prostaglandins (PGD₂ and PGJ₂, PGE₂, PGF_{2α}, PGI₂) and thromboxane A₂ (TXA₂) by respective synthases. COX, cyclooxygenase; PGES, prostaglandin E synthase; PGDS, prostaglandin D synthase; PGFS, prostaglandin F synthase; PGIS, prostacyclin synthase; TXS, thromboxane synthase. Individual prostaglandin interacts with specific members of the subfamily of the G protein-coupled receptor (GPCR) superfamily of seven transmembrane-spanning proteins, DP₁, DP₂, EP_{1–4}, FP, IP, and TP. Then, these receptors activate different transduction (cAMP/ Ca²⁺) and signaling pathways.

of PGES to that of lipocalin PGDS (L-PGDS) (Schuligoi *et al.* 2005, Nicolaou *et al.* 2014).

PGD₂ synthesis and its regulation

PGD₂ synthesis is regulated by the functional and differential coupling of COX1 and COX2 enzymes with both PGDS and PGES (Ueno *et al.* 2005). The expression of COX2 is induced by growth factors such as pro-inflammatory cytokines (IL1, TNFα), and inhibited by glucocorticoids and other anti-inflammatory cytokines (IL4 and IL10) (Loftin *et al.* 2002, Morita 2002). In particular, COX2 is induced by interleukin-1 in the testes of infertile men, stimulating the production of PGD₂ and PGF_{2α} (Matzkin *et al.* 2010). Testosterone induces COX2 expression and PGF_{2α} production in hamster Leydig cells through a nonclassical mechanism involving MAPK signaling (Matzkin *et al.* 2009). Silencing of *Ptgs2* through G9a- and EZH2-mediated histone methylation and DNA methylation of its promoter region has also been reported (Coward *et al.* 2014). On the other hand, the nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit COX enzymatic activities through noncompetitive (Aspirin) or competitive binding to the active site (Cha *et al.* 2006).

The synthesis of PGD₂ is under the specific control of two PGDS, the L-PGDS (or PTGDS), and the H-PGDS (or PTGDS2) (Urade & Eguchi 2002). Originally identified in the rat brain, L-PGDS, whose function is independent of the tripeptide glutathione, is part of the lipocalin protein superfamily, the members of which are secreted into the extracellular space (Urade *et al.* 1985, Urade & Hayaishi 2000a). This enzyme is produced in the CNS (brain, spinal cord, dorsal root ganglia), in the male genitalia (testes, epididymides, prostate) (Fouchecourt *et al.* 2002), and in the heart (Eguchi *et al.* 1997). It has been suggested that L-PGDS has dual functions. Associated with the endoplasmic reticulum and the outer nuclear membrane, it catalyzes the final step in PGD₂ synthesis from a common PG precursor. Secondly, as L-PGDS is secreted in many fluids (cerebrospinal fluid, seminal plasma, ascites, serum, urine, and amniotic fluid), it has been proposed to have a role in binding and transporting small hydrophobic ligands such as retinol, β-lactoglobulin, bile pigments, and thyroid hormones (Urade & Hayaishi 2000b, Fouchecourt *et al.* 2002).

The expression of *L-Pgds* is also under the control of many regulatory factors, protein kinase C (PKC) (Fujimori *et al.* 2005), estrogens (Mong *et al.* 2003), IL1β, RasGRP4

Table 1 Abbreviations.

COX1 or PTGS1: Cyclooxygenase 1 or prostaglandin G/H synthase 1
COX2 or PTGS2: Cyclooxygenase 2
DP ₁ : Prostaglandin D ₂ receptor 1
DP ₂ or CRTH ₂ : Prostaglandin D ₂ receptor 2
H-PGDS or PTGDS2: Hematopoietic-type prostaglandin D ₂ synthase
HQL-79: 4-benzhydryloxy-1-[3-(1H-tetrazol-5-yl)-propyl]-piperidine
L-PGDS or PTGDS: Lipocalin-type prostaglandin D ₂ synthase
NSAIDs:
PG: Prostaglandins
PGD ₂ : Prostaglandin D ₂
PGDS: Prostaglandin D synthase
PGE ₂ : Prostaglandin E ₂
PGES: Prostaglandin E synthase
PGF _{2α} : Prostaglandin F _{2α}
PGFS: Prostaglandin F synthase
PGG ₂ : Prostaglandin G ₂
PGH ₂ : Prostaglandin H ₂
PGI ₂ : Prostaglandin I ₂ or prostacyclin
PGIS: Prostaglandin I synthase
TxA ₂ : thromboxane A ₂
TXS: Thromboxane A synthase

(Li *et al.* 2003), each being highly cell-type specific. PGD₂ itself induces *L-Pgds* expression through binding of the Nrf2 factor on the *L-Pgds* promoter region in macrophages (Kim *et al.* 2013). *In vitro* primary cultures of rat Sertoli cells also show the activation of L-PGDS protein expression after treatment with progesterone or retinoic acid (RA) (Samy *et al.* 2000). RA strongly induces the accumulation of *L-PGDS* mRNA in human 3AO ovarian cancer cells, leading to the inhibition of their proliferation (Su *et al.* 2003). Furthermore, in the embryonic male gonad, *L-PGDS* expression is initiated and maintained by the testis differentiating factor SOX9 (Moniot *et al.* 2009) (see below).

Originally identified in the rat spleen, H-PGDS is a member of the class of glutathione-S-transferase enzymes, which are cytosolic and play a role in detoxification. Bivalent Ca²⁺ and Mg²⁺ ions increase the activity of H-PGDS; however, only Mg²⁺ increases its affinity for glutathione (Inoue *et al.* 2003). Despite the high homology of the primary sequence in different species, the tissue expression profile is highly variable. Expression is high in the peripheral tissue, spleen, thymus, bone marrow, gastrointestinal tract, and oviduct of rats (Kanaoka & Urade 2003). In the mouse, expression is predominant in the skin, oviduct (Kanaoka *et al.* 2000), and granulosa cells of the postnatal and adult ovary (Farhat *et al.* 2011). However, in humans, expression is found in the placenta, lung, fetal liver, heart, brain, mastocytes, lymphocytes, Th2 cells, and antigen-presenting cells (Kanaoka *et al.* 2000, Tanaka *et al.* 2000).

PGD₂ is dehydrated *in vitro* and *in vivo* by a non-enzymatic process to produce PGs of the J series, PGJ₂, and 15-deoxy ¹²⁻¹⁴-PGJ₂ (15-d PGJ₂) (Shibata *et al.* 2002). These PGD₂ metabolites can also influence diverse cellular functions. In particular, H-PGDS was shown to control the onset and resolution of acute inflammation through PGD₂ and 15-d PGJ₂ (Rajakari *et al.* 2007).

PGD₂ signal transduction

PGs are secreted and activate nine different receptors (Fig. 1): DP₁ and DP₂ or chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH₂) for PGD₂, EP₁₋₄ for PGE₂, FP for PGF_{2α}, IP for PGI₂, and TP for TxA₂ (Breyer *et al.* 2001). PG receptors are categorized as three clusters of a distinct subfamily of the G protein-coupled receptor (GCPR) superfamily of seven transmembrane-spanning proteins (Coleman *et al.* 1994). The only exception is DP₂, a member of the chemoattractant receptor subgroup. These receptors transduce different signals via the production of second messenger cAMP or IP₃/diacylglycerol/Ca²⁺ (Woodward *et al.* 2011) (Fig. 1).

Thus, PGD₂ may bind to two receptors, the DP₁ receptor (Boie *et al.* 1995) and/or the DP₂ receptor CRTH₂ (Hirai *et al.* 2001). Activation of the DP₁ receptor, coupled to a G_{αs} protein, induces the production of the second messenger cAMP, which stimulates protein kinase A (PKA) and also induces an influx of Ca²⁺ (Boie *et al.* 1995). The activation of CRTH₂ or DP₂ receptors coupled to a G_{αi} protein inhibits cAMP production (Hirai *et al.* 2001) and induces intracellular Ca²⁺ mobilization caused by the production of inositol triphosphate (Woodward *et al.* 2011). On the other hand, the PGD₂ metabolite 15d-PGJ₂ was identified as a ligand for the peroxisome proliferator-activated receptor gamma (PPARγ), a member of the nuclear receptor family (Forman *et al.* 1995) and for DP₂.

PGD₂ and reproduction in adult gonads

Female reproduction

Few studies have evaluated the involvement of PGD₂ in female reproduction. H-PGDS and both DP₁ and CRTH₂ receptors are expressed in the placenta and L-PGDS is present in amniotic fluid, indicating a role in the regulation of placental communication (Lumsden *et al.* 1986, Saito *et al.* 2002). *H-Pgds* mRNA was localized in the granulosa cells from primary to pre-ovulatory follicles of the mouse adult ovary (Farhat *et al.* 2011). In this tissue, H-PGDS-induced PGD₂ interferes with FSH signaling through increased *Fshr* and *Lhcgr* (*LhR*) receptor expression, leading to the activation of steroidogenic *Cyp11a1* and *Star* gene expression, and subsequently to progesterone secretion. Furthermore, H-PGDS-induced PGD₂ is involved in the regulation of follicular growth through inhibition of granulosa cell proliferation in growing follicles (Farhat *et al.* 2011).

However, numerous roles of other PGs, PGE₂, PGF_{2α}, and PGI₂ have been highlighted in different stages of blastocyst implantation: vascular permeabilization, stromal decidualization, blastocyst growth and development, leukocyte recruitment, embryo transport, trophoblast invasion, and extracellular matrix remodeling (Salleh 2014). The respective contribution of these PGs

in female reproduction was highlighted through the analysis of the *Cox1* and/or *Cox2*-knockout mice (Morita 2002). In particular, *Cox2* gene-deficient mice have defective ovulation, fertilization, and implantation mechanisms (Loftin *et al.* 2001). This phenotype was mimicked in *Ep2^{-/-}* receptor mice, demonstrating the involvement of PGE₂ in these processes. COX2, PGE₂, and Ptger2, synthesized in follicular cumulus cells in response to gonadotropins, induce the follicle and oocyte maturation necessary for fertilization and ovulation (Kobayashi & Narumiya 2002). Furthermore, mice with targeted disruption of the *Cox1* gene have delayed parturition resulting in neonatal death, demonstrating the role of *Cox1* for the initiation of labor (Gross *et al.* 1998). PGF_{2α}, which is highly expressed in the uterus, is involved in this process via the FP receptor. Moreover, PGF_{2α} expression in the corpus luteum of the ovary is also involved in the apoptosis of these cells in the absence of gestation (Hasumoto *et al.* 1997).

Male reproduction

In the male, *Cox1^{-/-}* and *Cox2^{-/-}* mouse models do not exhibit perturbed reproductive processes. However, L-PGDS is widely expressed in the testis and caput epididymis of bull and mouse models (Gerena *et al.* 2000a,b). L-PGDS is detected in bovine and human seminal plasma (Gerena *et al.* 1998, Tokugawa *et al.* 1998) and its concentration is lower in oligozoospermic than in normozoospermic men (Tokugawa *et al.* 1998), suggesting that this protein plays a role in both the development and maturation of sperm and emphasizes the role of L-PGDS in spermatogenesis. *L-Pgds* mRNA expression is found mainly in Leydig cells (Baker & O'Shaughnessy 2001), prospermatogonia, and SOX9-expressing Sertoli cells (Moniot *et al.* 2009) of the adult mouse testis. In rat, L-PGDS was detected in the Sertoli and germ cells of the adult testis (Samy *et al.* 2000). In humans, L-PGDS, H-PGDS, and DP₁ receptor are also expressed in the interstitial compartments of testes with normal and impaired spermatogenesis (Schell *et al.* 2007). L-PGDS and H-PGDS are expressed in Leydig cells and mast cells, respectively, along with COX2, in testes with impaired spermatogenesis. COX1 and COX2 are shown to be absent in normal human testes, whereas they are highly expressed in testicular cancer, and act to induce the growth of testicular cancer cells (Hase *et al.* 2003). The expression of COX2 in testicular biopsies from patients with mixed atrophy is correlated with H-PGDS expression in the mast cells of these testes (Welter *et al.* 2011). The major function of L-PGDS in spermatogenesis may be related with its role in the supply of retinoids, thyroid hormones, and essential fatty acids for the development of germ cells in the seminiferous tubules and maturing spermatozoa in the epididymides (Urade & Hayaishi 2000a). However, the role of L-PGDS in male reproduction remains unclear (Leone *et al.* 2002).

H-PGDS expression in the male gonad is not well documented. The expression was detected in the Leydig cells and mast cells of the testes of human patients with impaired spermatogenesis (Schell *et al.* 2007) and in the germ cells of murine testes (personal data not shown); however, its role in reproduction is unknown.

15-Deoxy PGJ₂, a metabolite of PGD₂ influences the expression of differentiation markers (SMC, smooth muscle actin) and the contractibility of the human peritubular cells of the testes (Schell *et al.* 2010) and thus, may be involved in infertility (Welter *et al.* 2013). COX2 mRNA expression was greatly increased in experimental cryptorchid testes, when compared with contralateral testes. Furthermore, in the spermatocytes of the cryptorchid testes the COX2 protein was specifically upregulated, thus protecting germ cells against apoptosis and disturbance of spermatogenesis (Kubota *et al.* 2011).

Furthermore, PGD₂ induced testosterone production in Leydig cells isolated from hamster testes (Schell *et al.* 2007). On the other hand, COX2 activity was shown to reduce steroidogenesis by decreasing *Star* gene expression in MA-10 mouse Leydig cells (Wang *et al.* 2003). However, the role of PGD₂ in the steroidogenesis process is still unclear because other reports using organotypic cultures of adult human gonads did not find a link between the effect of analgesics on PG synthesis and inhibition of testosterone production (Albert *et al.* 2013).

PGD₂ and the formation of embryonic male gonads

PGD₂ signaling components are expressed in embryonic testes

Amongst the male-enriched bands, identified by representational difference analysis (RDA) at embryonic stage E12.5, the gene encoding for L-PGDS was identified (Adams & McLaren 2002). The expression of *L-Pgds* mRNA in developing urogenital ridges was first detected in the Sertoli cells and prospermatogonia of late E11.5 male genital ridges (Adams & McLaren 2002). The expression of *L-Pgds* mRNAs in both somatic and germ cell compartments was confirmed at E13.5, although somatic expression was higher than that of germ cells (Moniot *et al.* 2014). *L-Pgds* showed similar expression profiles to *Sox9* and *Fgf9*, with expression starting at mid-late E11.5 and progressing to a plateau at E12.5 (Wilhelm *et al.* 2005). *L-Pgds* expression was described as a dynamic wave-like expression pattern, closely resembling that of *Sry* and *Sox9* in the embryonic testis. *L-Pgds* transcripts were detected in the center of the testis at the 17 tail somites (Ts) stage, shortly after the onset of *Sox9* expression at 15 Ts, and were shown to be upregulated at 21 Ts (Wilhelm *et al.* 2007). L-PGDS protein expression was evident in the E12.5 male gonads, in both the Sertoli and germ cells (Moniot *et al.* 2009). *L-Pgds* mRNA expression shifts from the

seminiferous tubules in the embryonic gonad and neonatal testis to the interstitial compartment, particularly the Leydig cells in the adult testis (Baker & O'Shaughnessy 2001, Moniot *et al.* 2009).

Concerning the second PGD₂-inducing H-Pgds enzyme, *H-Pgds* mRNA expression in both germ and somatic cells was found in E11.5–E17.5 gonads. In addition, the H-PGDS protein is also expressed in both cell types (Moniot *et al.* 2011, 2014). Production of PGD₂ by both the somatic and germ cell lineages was confirmed, using chemical fixation of PGD₂ on its production site (Bandeira-Melo *et al.* 2011) followed by immunofluorescence analysis, suggesting that both L-PGDS and H-PGDS enzyme capabilities are active within the embryonic gonad (Moniot *et al.* 2014). On the other hand, in the E13.5 male gonad, the DP₁ receptor is only expressed in somatic cells whereas the DP₂ is expressed in both germ cells and somatic compartments, at the mRNA and protein levels (Moniot *et al.* 2014).

PGD₂ signaling is involved in somatic differentiation

In most mammals, somatic sex determination in males is initiated in undifferentiated embryonic gonads by the expression of the *Sry* gene, which occurs at stages E10.5–E12.5 in mice, initiating testis differentiating *Sox9* gene expression (Sekido & Lovell-Badge 2008). The master effector gene *Sox9* encodes a transcription factor that belongs to the HMG superfamily (Wagner *et al.* 1994). Before sex determination and before the peak of *Sry* expression at E11.5, SOX9 is excluded from the nucleus in the genital ridge of both sexes (Morais da Silva *et al.* 1996, de Santa Barbara *et al.* 2000), via a nuclear export signal (NES), located in its HMG domain (Gasca *et al.* 2002), and is retained in the cytoplasm, possibly via its interaction with microtubules (Malki *et al.* 2005a). Upon sex determination, the SOX9 protein is transported into the nucleus in the male gonad. PGD₂ signaling via its DP₁ receptor and stimulation of the cAMP pathway induce SOX9 nuclear translocation via PKA phosphorylation in NT2/D1 cells (Malki *et al.* 2005b) (Fig. 2). Indeed, in *L-Pgds*^{−/−} gonads, SOX9 subcellular localization and testis cord formation were impaired up to E13.5, even though a variable SOX9 expression pattern and sex cord formation phenotype, ranging from normal to severely abnormal, were found (Moniot *et al.* 2009). Furthermore, the PGD₂-producing H-PGDS enzyme is expressed in the embryonic gonad at mid E11.5 (16–17 Ts), despite L-PGDS not being expressed. Inhibition of H-Pgds enzymatic activity by the specific HQL-79 inhibitor impairs nuclear translocation of the SOX9 protein in E11.5 pre-Sertoli cells, a phenotype that was also found in *H-Pgds*^{−/−} XY gonads (Moniot *et al.* 2011), suggesting that an initial H-PGDS-mediated PGD₂ signal could participate in the SOX9 nuclear translocation necessary for the process of Sertoli cell differentiation (Fig. 2).

Moreover, PGD₂ has a masculinizing effect on cultivated XX gonadal explants (ectopic testicular cord formation and expression of AMH) (Adams & McLaren 2002) through the stimulation of *Sox9* gene expression (Wilhelm *et al.* 2005), as SOX9 can directly bind to and activate the *L-Pgds* promoter (Wilhelm *et al.* 2007). *L-Pgds* expression was indeed abolished in E12.0 male *Sox9*^{−/−} gonads (*Ck19-Cre; Sox9*^{flox/flox} mice), confirming that SOX9 is required for the initiation of *L-Pgds* gene expression, as *L-Pgds* is a direct target gene for SOX9. Moreover, ablation of *Sox9* after the onset of *L-Pgds* expression (E13.5–E14.5 *Amh-Cre; Sox9*^{flox/flox}) also induces a strong downregulation of *L-Pgds* expression, demonstrating the requirement for the SOX9 protein in the maintenance of *L-Pgds* gene expression in embryonic Sertoli cells (Moniot *et al.* 2009). Altogether, these data show that *L-Pgds* and *Sox9* genes are part of a regulatory loop, initiating and maintaining *L-Pgds* expression and upregulating *Sox9*. This regulatory loop is independent on the fibroblast growth factor 9 (*Fgf9*)/*Sox9* regulatory loop previously identified (Kim *et al.* 2006). Indeed, the onset of *L-Pgds* expression was not affected in *Fgf9*^{−/−} (Moniot *et al.* 2009) or *Fgf9* receptor R2 (*FgfR2*^{−/−}) (Kim *et al.* 2007) mutant XY gonads and *Fgf9* mRNA expression was not modified in E12.5 *L-Pgds*^{−/−} gonads, confirming that both pathways do not interact genetically. However, both FGF9 and PGD₂ signaling molecules cooperate to additively upregulate *Sox9* expression in the Sertoli-like NT2D1 cell line (Moniot *et al.* 2009; Fig. 2). Many endocrine disruptors (phthalates, bisphenol) and several NSAIDs that inhibit COX activities reduce PGD₂ production in the SC5 mouse Sertoli cell line and in cultured rat fetal testes (Kristensen *et al.* 2011a,b, 2012), leading to reduced testosterone production. However, the role of PGD₂ in the onset of the steroidogenesis process remains unclear. Unlike adult human or rat testes, *ex vivo* exposure of embryonic human testis to paracetamol, aspirin, and indomethacin has no effect either on the production of PGD₂ or on the concentration of testosterone (Mazaud-Guittot *et al.* 2013).

PGD₂ is also involved in the process of testicular descent in mice, because adult *L-Pgds*^{−/−} mice present unilateral cryptorchidism without impaired androgen signaling, but rather a decrease in the INSL3 receptor *Rxfp2* mRNA expression in the gubernaculum (Philibert *et al.* 2013). The use of NSAIDs, which inhibit COXs enzymes, during the second trimester of pregnancy is associated with an increased risk of cryptorchidism in humans (Jensen *et al.* 2010, Kristensen *et al.* 2011a); however, the nature of the PG(s) involved in this phenotype is unknown.

PGD₂ signaling is involved in germ line differentiation

The differentiated Sertoli cells will then influence the germ cell lineage to differentiate (Svingen & Koopman 2013).

Figure 2 Model for the role of PGD₂ signaling in Sertoli cell and germ cell differentiation in the male embryonic gonad. Upon sex determination around E11.5, the Sertoli cell differentiating factor SOX9 is transported into the nucleus in the male gonad. PGD₂ signaling via its DP₁ receptor and stimulation of the cAMP pathway induces SOX9 nuclear translocation via protein kinase A (PKA) phosphorylation. PGD₂ signaling through *L-Pgds* is part of a regulatory loop between *L-Pgds* and *Sox9* genes, which acts independently of the FGF9/SOX9 loop. Later around E13.5, PGD₂ signaling, which is produced by both the Sertoli cell and germ cells, is involved in the germline differentiation, through its DP₂ receptor. PGD₂ is involved in the activation of the male germ cell marker *Nanos2*, inhibiting meiosis through the repression of *Stra8*; PGD₂ is also involved in the activation of the cell cycle inhibitor p21 expression and the repression of Cyclins E expression, and in the repression of the pluripotent markers expression *Sox2*, *Pou5f1*, and *Nanog*, contributing to the mitotic arrest of the male germline. On the other hand, PGD₂ produced in Sertoli cells activates *Notch1* and *Cyp26B1* gene expression, indirectly influencing the germ cell fate.

In mice, primordial germ cells (PGCs) colonize the genital ridge at around E10.5 and continue proliferating until E13.5 (McLaren 2000). At this time, in the developing ovary, germ cells enter prophase of the first meiotic division after the upregulation of the pre-meiotic gene *Stra8* (Ewen & Koopman 2010). In contrast, in the testis, germ cells stop proliferating and fully enter the G₀/G₁ phase of the cell cycle by E15.5 (Western *et al.* 2008); meanwhile, pluripotent marker expression is repressed (Western *et al.* 2010) and male germ cell markers such as *Nanos2* are upregulated, which actively inhibits meiosis entry and thus contributes to the differentiation of the germline (Suzuki & Saga 2008). Male germ cells remain quiescent until shortly after birth, at which point they resume mitosis and then initiate meiosis around 8 days post partum (dpp) (Ewen & Koopman 2010).

In vivo analysis of double-knockout *L/H-Pgds* (*L/H-Pgds*^{-/-}, i.e. depleted for PGD₂) gonads showed that the proliferation rate of E13.5 mutant germ cells increased by 1.5-fold compared with WT germ cells. At E15.5 and even E17.5, nearly 10% of

the mutant germ cells were still Ki-67 positive, showing that a significant proportion of the mutant germ cells were not mitotically arrested and were still engaged in the cell cycle at a time which should be quiescent (Moniot *et al.* 2014). Meanwhile, cell cycle inhibitors *p21*^{Cip1} and *p57*^{Kip2} are downregulated and cell cycle activators *CyclinE1* and *E2* are upregulated (Fig. 2), suggesting that PGD₂ signaling is involved in the control of cell cycle genes in fetal testes, contributing to the arrest of mitotic process. Moreover, at late embryonic stages, the ectopic expression of pluripotency markers *Pou5f1* (*Oct4*), *Sox2*, and *Nanog* was detected in *L/H-Pgds*^{-/-} testes and the male germ cell marker *Nanos2* is downregulated in mutant testes suggesting that PGD₂ has a role in the germ cell differentiation in the embryonic testis. Somatic factors, *Notch1* (Garcia *et al.* 2013) and *Cyp26B1*, an RA-metabolizing enzyme of the cytochrome P450 family that is produced by the Sertoli cells and that protects germ cells from RA (Bowles *et al.* 2006), were significantly reduced in E13.5 mutant gonads (Fig. 2), suggesting that PGD₂ produced by

Sertoli cells influences the differentiation of the embryonic germ cells (Moniot *et al.* 2014). Finally, the DP2 receptor is responsive to the effects of PGD₂ in the male germline, because *Dp2*^{-/-} testes have the same phenotype as that of the *L/H-Pgds*^{-/-} testes (Fig. 2; Moniot *et al.* 2014). PGD₂ signaling is thus an early pathway acting in both paracrine and autocrine manners (Fig. 2), contributing to the proper differentiation of male fetal germ cells.

Conclusions, perspectives

The development and maturation of the reproductive organs are complex and highly regulated biological mechanisms, in which numerous factors and signaling pathways are involved. In this review, we addressed the advancement of knowledge on PGD₂ signaling in female and male reproduction, particularly in the formation of embryonic gonads and the maturation of adult reproductive organs. Whereas PGD₂ signaling through both PGDSs is involved in the differentiation of the embryonic testis at the somatic and germ cell levels, its roles in steroidogenesis and spermatogenesis in adults are still under debate. The dual roles of the L-PGDS enzyme suggest that this protein plays a role in both the development and maturation of sperm and spermatogenesis. Seminal L-PGDS, an important carrier of bile pigments, retinoids, thyroid hormones, and essential fatty acids, would contribute to providing, beyond the blood–testis barrier, thyroid hormones, and retinoids to the developing germ cells in the seminiferous tubules and the maturing spermatozoa in the epididymis. Both PGDSs are indeed expressed in testes of patients with impaired spermatogenesis, suggesting their involvement in fertility (Leone *et al.* 2002).

The increasing incidence of disorders of the reproductive organs in men, such as cryptorchidism, hypospadias, decreased semen quality, and testosterone concentration, or testicular cancers, has been observed in recent decades (Toppari *et al.* 1996, Skakkebaek *et al.* 2001). The use of NSAIDs drugs during the second trimester of pregnancy is associated with an increased risk of cryptorchidism in humans (Jensen *et al.* 2010) and in rats (Kristensen *et al.* 2011a). As PGD₂ is a potential target for endocrine disruptors and NSAIDs, our findings thus open new perspectives for future investigations into how germ cell development can be perturbed by the external environment. Germ cells that are not controlled appropriately during fetal life can later transform into carcinoma *in situ* (CIS), the pluripotent precursor cells for testicular germ cell tumors (Kristensen *et al.* 2008). Indeed, PGD₂/DP₂ signaling is involved in the control of key regulators of the G₁/S phase checkpoint and in the repression of pluripotent markers' expression in the male embryonic germline; its ablation resulting in CIS-like phenotype in the mice gonad. Further work will determine whether the double *L/H-Pgds* mutation can

lead to a high incidence of germ-line tumors in the 129sv background. PGD₂ signaling through L-PGDS and SOX9 expression suppresses NT2/D1 cell migration and invasion, suggesting an important role for PGD₂ in cancer cell suppression in the testis (Wu *et al.* 2012). L-PGDS is abnormally expressed in ovarian tumors (Su *et al.* 2003, Malki *et al.* 2007). The antiproliferative effect of PGD₂ has been highlighted in human ovarian cancer cell lines (Kikuchi *et al.* 1986, Su *et al.* 2003); stimulation of the PGD₂/DP₁ signal transduction pathway upregulates SOX9 expression leading to the inhibition of cancer cells growth (Malki *et al.* 2007).

The recent findings, showing that endocrine disruptors and NSAIDs influence the PGD₂ production in the testes and that PGD₂ signaling is involved in multiples steps of the embryonic testis differentiation, might introduce this pathway in the etiology of the reproduction diseases. As the pharmacology of the PGD₂ signaling is well documented, either activators of this pathway or DP₁/DP₂ agonists may be useful as new therapeutic agents.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the review.

Funding

This research was supported by the French Agency for Research (ANR), Grant «MolMechMeiosis» and by National Agency for the Security of Medecine (ANSM), Grant 2013-041.

References

- Adams IR & McLaren A 2002 Sexually dimorphic development of mouse primordial germ cells: switching from oogenesis to spermatogenesis. *Development* **129** 1155–1164.
- Albert O, Desdoits-Lethimonier C, Lesne L, Legrand A, Guille F, Bensalah K, Dejucq-Rainsford N & Jegou B 2013 Paracetamol, aspirin and indomethacin display endocrine disrupting properties in the adult human testis *in vitro*. *Human Reproduction* **28** 1890–1898. (doi:10.1093/humrep/det112)
- Baker PJ & O'Shaughnessy PJ 2001 Expression of prostaglandin D synthetase during development in the mouse testis. *Reproduction* **122** 553–559. (doi:10.1530/rep.0.1220553)
- Bandeira-Melo C, Weller PF & Bozza PT 2011 EicosaCell – an immunofluorescent-based assay to localize newly synthesized eicosanoid lipid mediators at intracellular sites. *Methods in Molecular Biology* **689** 163–181. (doi:10.1007/978-1-60761-950-5_10)
- Boie Y, Sawyer N, Slipetz DM, Metters KM & Abramovitz M 1995 Molecular cloning and characterization of the human prostanoid DP receptor. *Journal of Biological Chemistry* **270** 18910–18916. (doi:10.1074/jbc.270.32.18910)
- Bowles J, Knight D, Smith C, Wilhelm D, Richman J, Mamiya S, Yashiro K, Chawengsaksophak K, Wilson MJ, Rossant J *et al.* 2006 Retinoid signaling determines germ cell fate in mice. *Science* **312** 596–600. (doi:10.1126/science.1125691)
- Breyer RM, Bagdassarian CK, Myers SA & Breyer MD 2001 Prostanoid receptors: subtypes and signaling. *Annual Review of Pharmacology and Toxicology* **41** 661–690. (doi:10.1146/annurev.pharmtox.41.1.661)

- Cha YI, Solnica-Krezel L & DuBois RN 2006 Fishing for prostanoids: deciphering the developmental functions of cyclooxygenase-derived prostaglandins. *Developmental Biology* **289** 263–272. (doi:10.1016/j.ydbio.2005.10.013)
- Coleman RA, Smith WL & Narumiya S 1994 International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. *Pharmacological Reviews* **46** 205–229.
- Coward WR, Feghali-Bostwick CA, Jenkins G, Knox AJ & Pang L 2014 A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis. *FASEB Journal* **28** 3183–3196. (doi:10.1096/fj.13-241760)
- Eguchi Y, Eguchi N, Oda H, Seiki K, Kijima Y, Matsu-ura Y, Urade Y & Hayaishi O 1997 Expression of lipocalin-type prostaglandin D synthase (β -trace) in human heart and its accumulation in the coronary circulation of angina patients. *PNAS* **94** 14689–14694. (doi:10.1073/pnas.94.26.14689)
- Ewen KA & Koopman P 2010 Mouse germ cell development: from specification to sex determination. *Molecular and Cellular Endocrinology* **323** 76–93. (doi:10.1016/j.mce.2009.12.013)
- Farhat A, Philibert P, Sultan C, Poulat F & Boizet-Bonhoure B 2011 Hematopoietic-prostaglandin D₂ synthase through PGD₂ production is involved in the adult ovarian physiology. *Journal of Ovarian Research* **4** 3. (doi:10.1186/1757-2215-4-3)
- Fincham N & Camp R 1983 Novel prostaglandin dehydrogenase in rat skin. *Biochemical Journal* **212** 129–134.
- Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM & Evans RM 1995 15-Deoxy- Δ 12, 14-prostaglandin J₂ is a ligand for the adipocyte determination factor PPAR γ . *Cell* **83** 803–812. (doi:10.1016/0092-8674(95)90193-0)
- Fouchecourt S, Charpigny G, Reinaud P, Dumont P & Dacheux JL 2002 Mammalian lipocalin-type prostaglandin D₂ synthase in the fluids of the male genital tract: putative biochemical and physiological functions. *Biology of Reproduction* **66** 458–467. (doi:10.1095/biolreprod66.2.458)
- Fujimori K, Kadoyama K & Urade Y 2005 Protein kinase C activates human lipocalin-type prostaglandin D synthase gene expression through de-repression of notch-HES signaling and enhancement of AP-2 β function in brain-derived TE671 cells. *Journal of Biological Chemistry* **280** 18452–18461. (doi:10.1074/jbc.M411755200)
- Gao W, Schmidtke A, Wobst I, Lu R, Angioni C & Geisslinger G 2009 Prostaglandin D₂ produced by hematopoietic prostaglandin D synthase contributes to LPS-induced fever. *Journal of Physiology and Pharmacology* **60** 145–150.
- Garcia TX, Defalco T, Capel B & Hofmann MC 2013 Constitutive activation of NOTCH1 signaling in Sertoli cells causes gonocyte exit from quiescence. *Developmental Biology* **377** 188–201. (doi:10.1016/j.ydbio.2013.01.031)
- Gasca S, Canizares J, De Santa Barbara P, Mejean C, Poulat F, Berta P & Boizet-Bonhoure B 2002 A nuclear export signal within the high mobility group domain regulates the nucleocytoplasmic translocation of SOX9 during sexual determination. *PNAS* **99** 11199–11204. (doi:10.1073/pnas.172383099)
- Gerena RL, Irikura D, Urade Y, Eguchi N, Chapman DA & Killian GJ 1998 Identification of a fertility-associated protein in bull seminal plasma as lipocalin-type prostaglandin D synthase. *Biology of Reproduction* **58** 826–833. (doi:10.1095/biolreprod58.3.826)
- Gerena RL, Eguchi N, Urade Y & Killian GJ 2000a Stage and region-specific localization of lipocalin-type prostaglandin D synthase in the adult murine testis and epididymis. *Journal of Andrology* **21** 848–854.
- Gerena RL, Irikura D, Eguchi N, Urade Y & Killian GJ 2000b Immunocytochemical localization of lipocalin-type prostaglandin D synthase in the bull testis and epididymis and on ejaculated sperm. *Biology of Reproduction* **62** 547–556. (doi:10.1095/biolreprod62.3.547)
- Gross GA, Imamura T, Luedke C, Vogt SK, Olson LM, Nelson DM, Sadovsky Y & Muglia LJ 1998 Opposing actions of prostaglandins and oxytocin determine the onset of murine labor. *PNAS* **95** 11875–11879. (doi:10.1073/pnas.95.20.11875)
- Hase T, Yoshimura R, Matsuyama M, Kawahito Y, Wada S, Tsuchida K, Sano H & Nakatani T 2003 Cyclooxygenase-1 and -2 in human testicular tumours. *European Journal of Cancer* **39** 2043–2049. (doi:10.1016/S0959-8049(03)00485-4)
- Hasumoto K, Sugimoto Y, Yamasaki A, Morimoto K, Kakizuka A, Negishi M & Ichikawa A 1997 Association of expression of mRNA encoding the PGF_{2 α} receptor with luteal cell apoptosis in ovaries of pseudopregnant mice. *Journal of Reproduction and Fertility* **109** 45–51. (doi:10.1530/jrf.0.1090045)
- Hata AN & Breyer RM 2004 Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. *Pharmacology and Therapeutics* **103** 147–166. (doi:10.1016/j.pharmthera.2004.06.003)
- Herlong JL & Scott TR 2006 Positioning prostanoids of the D and J series in the immunopathogenic scheme. *Immunology Letters* **102** 121–131. (doi:10.1016/j.imlet.2005.10.004)
- Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, Ichimasa M, Sugamura K, Nakamura M, Takano S *et al.* 2001 Prostaglandin D₂ selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH₂. *Journal of Experimental Medicine* **193** 255–261. (doi:10.1084/jem.193.2.255)
- Huang ZL, Urade Y & Hayaishi O 2007 Prostaglandins and adenosine in the regulation of sleep and wakefulness. *Current Opinion in Pharmacology* **7** 33–38. (doi:10.1016/j.coph.2006.09.004)
- Inoue T, Irikura D, Okazaki N, Kinugasa S, Matsumura H, Uodome N, Yamamoto M, Kumasaka T, Miyano M, Kai Y *et al.* 2003 Mechanism of metal activation of human hematopoietic prostaglandin D synthase. *Nature Structural Biology* **10** 291–296. (doi:10.1038/nsb907)
- Jensen MS, Rebordosa C, Thulstrup AM, Toft G, Sorensen HT, Bonde JP, Henriksen TB & Olsen J 2010 Maternal use of acetaminophen, ibuprofen, and acetylsalicylic acid during pregnancy and risk of cryptorchidism. *Epidemiology* **21** 779–785. (doi:10.1097/EDE.0b013e3181f20bed)
- Kanaoka Y & Urade Y 2003 Hematopoietic prostaglandin D synthase. *Prostaglandins, Leukotrienes, and Essential Fatty Acids* **69** 163–167. (doi:10.1016/S0952-3278(03)00077-2)
- Kanaoka Y, Fujimori K, Kikuno R, Sakaguchi Y, Urade Y & Hayaishi O 2000 Structure and chromosomal localization of human and mouse genes for hematopoietic prostaglandin D synthase. Conservation of the ancestral genomic structure of sigma-class glutathione S-transferase. *European Journal of Biochemistry* **267** 3315–3322. (doi:10.1046/j.1432-1327.2000.01362.x)
- Kikuchi Y, Miyauchi M, Oomori K, Kita T, Kizawa I & Kato K 1986 Inhibition of human ovarian cancer cell growth *in vitro* and in nude mice by prostaglandin D₂. *Cancer Research* **46** 3364–3366.
- Kim Y, Kobayashi A, Sekido R, DiNapoli L, Brennan J, Chaboissier MC, Poulat F, Behringer RR, Lovell-Badge R & Capel B 2006 Fgf9 and Wnt4 act as antagonistic signals to regulate mammalian sex determination. *PLoS Biology* **4** e187. (doi:10.1371/journal.pbio.0040187)
- Kim Y, Bingham N, Sekido R, Parker KL, Lovell-Badge R & Capel B 2007 Fibroblast growth factor receptor 2 regulates proliferation and Sertoli differentiation during male sex determination. *PNAS* **104** 16558–16563. (doi:10.1073/pnas.0702581104)
- Kim KH, Sadikot RT, Xiao L, Christman JW, Freeman ML, Chan JY, Oh YK, Blackwell TS & Joo M 2013 Nrf2 is essential for the expression of lipocalin-prostaglandin D synthase induced by prostaglandin D₂. *Free Radical Biology & Medicine* **65** 1134–1142. (doi:10.1016/j.freeradbiomed.2013.08.192)
- Kobayashi T & Narumiya S 2002 Function of prostanoid receptors: studies on knockout mice. *Prostaglandins & Other Lipid Mediators* **68–69** 557–573. (doi:10.1016/j.freeradbiomed.2013.08.192)
- Kristensen DM, Sonne SB, Ottesen AM, Perrett RM, Nielsen JE, Almstrup K, Skakkebaek NE, Leffers H & Meyts ER 2008 Origin of pluripotent germ cell tumours: the role of microenvironment during embryonic development. *Molecular and Cellular Endocrinology* **288** 111–118. (doi:10.1016/j.mce.2008.02.018)
- Kristensen DM, Hass U, Lesne L, Lottstrup G, Jacobsen PR, Desdoits-Lethimonier C, Boberg J, Petersen JH, Toppari J, Jensen TK *et al.* 2011a Intrauterine exposure to mild analgesics is a risk factor for development of male reproductive disorders in human and rat. *Human Reproduction* **26** 235–244. (doi:10.1093/humrep/deq323)
- Kristensen DM, Skalkam ML, Audouze K, Lesne L, Desdoits-Lethimonier C, Frederiksen H, Brunak S, Skakkebaek NE, Jegou B, Hansen JB *et al.* 2011b Many putative endocrine disruptors inhibit prostaglandin synthesis. *Environmental Health Perspectives* **119** 534–541. (doi:10.1289/ehp.1002635)

- Kristensen DM, Lesne L, Le Fol V, Desdoits-Lethimonier C, Dejucq-Rainsford N, Leffers H & Jegou B 2012 Paracetamol (acetaminophen), aspirin (acetylsalicylic acid) and indomethacin are anti-androgenic in the rat foetal testis. *International Journal of Andrology* **35** 377–384. (doi:10.1111/j.1365-2605.2012.01282.x)
- Kubota H, Sasaki S, Kubota Y, Umemoto Y, Yanai Y, Tozawa K, Hayashi Y & Kohri K 2011 Cyclooxygenase-2 protects germ cells against spermatogenesis disturbance in experimental cryptorchidism model mice. *Journal of Andrology* **32** 77–85. (doi:10.2164/jandrol.109.008888)
- Leone MG, Haq HA & Saso I 2002 Lipocalin type prostaglandin D-synthase: which role in male fertility? *Contraception* **65** 293–295. (doi:10.1016/S0010-7824(02)00280-9)
- Li L, Yang Y & Stevens RL 2003 RasGRP4 regulates the expression of prostaglandin D₂ in human and rat mast cell lines. *Journal of Biological Chemistry* **278** 4725–4729. (doi:10.1074/jbc.C200635200)
- Loftin CD, Trivedi DB, Tiano HF, Clark JA, Lee CA, Epstein JA, Morham SG, Breyer MD, Nguyen M, Hawkins BM *et al.* 2001 Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. *PNAS* **98** 1059–1064. (doi:10.1073/pnas.98.3.1059)
- Loftin CD, Tiano HF & Langenbach R 2002 Phenotypes of the COX-deficient mice indicate physiological and pathophysiological roles for COX-1 and COX-2. *Prostaglandins & Other Lipid Mediators* **68–69** 177–185. (doi:10.1073/pnas.98.3.1059)
- Lumsden MA, Kelly RW, Templeton AA, Van Look PF, Swanston IA & Baird DT 1986 Changes in the concentration of prostaglandins in preovulatory human follicles after administration of hCG. *Journal of Reproduction and Fertility* **77** 119–124. (doi:10.1530/jrf.0.0770119)
- Malki S, Berta P, Poulat F & Boizet-Bonhoure B 2005a Cytoplasmic retention of the sex-determining factor SOX9 via the microtubule network. *Experimental Cell Research* **309** 468–475. (doi:10.1016/j.yexcr.2005.07.005)
- Malki S, Nef S, Notarnicola C, Thevenet L, Gasca S, Mejean C, Berta P, Poulat F & Boizet-Bonhoure B 2005b Prostaglandin D₂ induces nuclear import of the sex-determining factor SOX9 via its cAMP-PKA phosphorylation. *EMBO Journal* **24** 1798–1809. (doi:10.1038/sj.emboj.7600660)
- Malki S, Bibeau F, Notarnicola C, Roques S, Berta P, Poulat F & Boizet-Bonhoure B 2007 Expression and biological role of the prostaglandin D synthase/SOX9 pathway in human ovarian cancer cells. *Cancer Letters* **255** 182–193. (doi:10.1016/j.canlet.2007.04.007)
- Matsuoka T, Hirata M, Tanaka H, Takahashi Y, Murata T, Kabashima K, Sugimoto Y, Kobayashi T, Ushikubi F, Aze Y *et al.* 2000 Prostaglandin D₂ as a mediator of allergic asthma. *Science* **287** 2013–2017. (doi:10.1126/science.287.5460.2013)
- Matzkin ME, Gonzalez-Calvar SI, Mayerhofer A, Calandra RS & Frungieri MB 2009 Testosterone induction of prostaglandin-endoperoxide synthase 2 expression and prostaglandin F(2 α) production in hamster Leydig cells. *Reproduction* **138** 163–175. (doi:10.1530/REP-09-0023)
- Matzkin ME, Mayerhofer A, Rossi SP, Gonzalez B, Gonzalez CR, Gonzalez-Calvar SI, Terradas C, Ponzio R, Puigdomenech E, Levallo O *et al.* 2010 Cyclooxygenase-2 in testes of infertile men: evidence for the induction of prostaglandin synthesis by interleukin-1 β . *Fertility and Sterility* **94** 1933–1936. (doi:10.1016/j.fertnstert.2010.01.039)
- Mazaud-Guittot S, Nicolas Nicolaz C, Desdoits-Lethimonier C, Coiffec I, Ben Maamar M, Balaguer P, Kristensen DM, Chevrier C, Lavoue V, Poulain P *et al.* 2013 Paracetamol, aspirin, and indomethacin induce endocrine disturbances in the human fetal testis capable of interfering with testicular descent. *Journal of Clinical Endocrinology and Metabolism* **98** E1757–E1767. (doi:10.1210/jc.2013-2531)
- McLaren A 2000 Germ and somatic cell lineages in the developing gonad. *Molecular and Cellular Endocrinology* **163** 3–9. (doi:10.1016/S0303-7207(99)00234-8)
- Mong JA, Devidze N, Frail DE, O'Connor LT, Samuel M, Choleris E, Ogawa S & Pfaff DW 2003 Estradiol differentially regulates lipocalin-type prostaglandin D synthase transcript levels in the rodent brain: evidence from high-density oligonucleotide arrays and *in situ* hybridization. *PNAS* **100** 318–323. (doi:10.1073/pnas.262663799)
- Moniot B, Declosmenil F, Barrionuevo F, Scherer G, Aritake K, Malki S, Marzi L, Cohen-Solal A, Georg I, Klattig J *et al.* 2009 The PGD₂ pathway, independently of FGF9, amplifies SOX9 activity in Sertoli cells during male sexual differentiation. *Development* **136** 1813–1821. (doi:10.1242/dev.032631)
- Moniot B, Farhat A, Aritake K, Declosmenil F, Nef S, Eguchi N, Urade Y, Poulat F & Boizet-Bonhoure B 2011 Hematopoietic prostaglandin D synthase (H-Pgds) is expressed in the early embryonic gonad and participates to the initial nuclear translocation of the SOX9 protein. *Developmental Dynamics* **240** 2335–2343. (doi:10.1002/dvdy.22726)
- Moniot B, Ujjan S, Champagne J, Hirai H, Aritake K, Nagata K, Dubois E, Nidelet S, Nakamura M, Urade Y *et al.* 2014 Prostaglandin D₂ acts through the Dp₂ receptor to influence male germ cell differentiation in the foetal mouse testis. *Development* **141** 3561–3571. (doi:10.1242/dev.103408)
- Morais da Silva S, Hacker H, Harley V, Goodfellow PN, Swain A & Lovell-Badge R 1996 Sox9 expression during gonadal development implies a conserved role for the gene in testis differentiation in mammals and birds. *Nature Genetics* **13** 62–68. (doi:10.1038/ng0996-62)
- Morita I 2002 Distinct functions of COX-1 and COX-2. *Prostaglandins & Other Lipid Mediators* **68–69** 165–175.
- Nicolaou A, Mauro C, Urquhart P & Marelli-Berg F 2014 Polyunsaturated fatty acid-derived lipid mediators and T cell function. *Frontiers in Immunology* **5** 75. (doi:10.3389/fimmu.2014.00075)
- Nieves A & Garza LA 2014 Does prostaglandin D₂ hold the cure to male pattern baldness? *Experimental Dermatology* **23** 224–227. (doi:10.1111/exd.12348)
- Oguma T, Asano K & Ishizaka A 2008 Role of prostaglandin D(2) and its receptors in the pathophysiology of asthma. *Allergy International* **57** 307–312. (doi:10.2332/allergolint.08-RAI-0033)
- Philibert P, Boizet-Bonhoure B, Bashamboo A, Paris F, Aritake K, Urade Y, Leger J, Sultan C & Poulat F 2013 Unilateral cryptorchidism in mice mutant for Ptgds. *Human Mutation* **34** 278–282. (doi:10.1002/humu.22231)
- Qu WM, Huang ZL, Xu XH, Aritake K, Eguchi N, Nambu F, Narumiya S, Urade Y & Hayaishi O 2006 Lipocalin-type prostaglandin D synthase produces prostaglandin D₂ involved in regulation of physiological sleep. *PNAS* **103** 17949–17954. (doi:10.1073/pnas.0608581103)
- Rajakari R, Hilliard M, Lawrence T, Trivedi S, Colville-Nash P, Bellingan G, Fitzgerald D, Yaqoob MM & Gilroy DW 2007 Hematopoietic prostaglandin D₂ synthase controls the onset and resolution of acute inflammation through PGD₂ and 15-deoxyDelta12 14 PGJ₂. *PNAS* **104** 20979–20984. (doi:10.1073/pnas.0707394104)
- Saito S, Tsuda H & Michimata T 2002 Prostaglandin D₂ and reproduction. *American Journal of Reproductive Immunology* **47** 295–302. (doi:10.1034/j.1600-0897.2002.01113.x)
- Salleh N 2014 Diverse roles of prostaglandins in blastocyst implantation. *Scientific World Journal* **2014** 968141.
- Samy ET, Li JC, Grima J, Lee WM, Silvestrini B & Cheng CY 2000 Sertoli cell prostaglandin D₂ synthetase is a multifunctional molecule: its expression and regulation. *Endocrinology* **141** 710–721.
- de Santa Barbara P, Moniot B, Poulat F & Berta P 2000 Expression and subcellular localization of SF-1, SOX9, WT1, and AMH proteins during early human testicular development. *Developmental Dynamics* **217** 293–298. (doi:10.1002/(SICI)1097-0177(200003)217:3<293::AID-DVDY7>3.0.CO;2-P)
- Schell C, Frungieri MB, Albrecht M, Gonzalez-Calvar SI, Kohn FM, Calandra RS & Mayerhofer A 2007 A prostaglandin D₂ system in the human testis. *Fertility and Sterility* **88** 233–236. (doi:10.1016/j.fertnstert.2006.11.100)
- Schell C, Albrecht M, Spillner S, Mayer C, Kunz L, Kohn FM, Schwarzer U & Mayerhofer A 2010 15-Deoxy-delta 12-14-prostaglandin-J₂ induces hypertrophy and loss of contractility in human testicular peritubular cells: implications for human male fertility. *Endocrinology* **151** 1257–1268. (doi:10.1210/en.2009-1325)
- Schuligoi R, Grill M, Heinemann A, Peskar BA & Amann R 2005 Sequential induction of prostaglandin E and D synthases in inflammation. *Biochemical and Biophysical Research Communications* **335** 684–689. (doi:10.1016/j.bbrc.2005.07.130)
- Sekido R & Lovell-Badge R 2008 Sex determination involves synergistic action of SRY and SF1 on a specific Sox9 enhancer. *Nature* **453** 930–934. (doi:10.1038/nature06944)

- Shibata T, Kondo M, Osawa T, Shibata N, Kobayashi M & Uchida K 2002 15-deoxy-delta 12,14-prostaglandin D₂. A prostaglandin D₂ metabolite generated during inflammatory processes. *Journal of Biological Chemistry* **277** 10459–10466. (doi:10.1074/jbc.M110314200)
- Simmons DL, Botting RM & Hla T 2004 Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. *Pharmacological Reviews* **56** 387–437. (doi:10.1124/pr.56.3.3)
- Skakkebaek NE, Rajpert-De Meyts E & Main KM 2001 Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. *Human Reproduction* **16** 972–978. (doi:10.1093/humrep/16.5.972)
- Su B, Guan M, Xia J & Lu Y 2003 Stimulation of lipocalin-type prostaglandin D synthase by retinoic acid coincides with inhibition of cell proliferation in human 3AO ovarian cancer cells. *Cell Biology International* **27** 587–592. (doi:10.1016/S1065-6995(03)00100-8)
- Suzuki A & Saga Y 2008 Nanos2 suppresses meiosis and promotes male germ cell differentiation. *Genes and Development* **22** 430–435. (doi:10.1101/gad.1612708)
- Svingen T & Koopman P 2013 Building the mammalian testis: origins, differentiation, and assembly of the component cell populations. *Genes and Development* **27** 2409–2426. (doi:10.1101/gad.228080.113)
- Tanaka K, Ogawa K, Sugamura K, Nakamura M, Takano S & Nagata K 2000 Cutting edge: differential production of prostaglandin D₂ by human helper T cell subsets. *Journal of Immunology* **164** 2277–2280. (doi:10.4049/jimmunol.164.5.2277)
- Taniguchi H, Mohri I, Okabe-Araho H, Aritake K, Wada K, Kanekiyo T, Narumiya S, Nakayama M, Ozono K, Urade Y *et al.* 2007 Prostaglandin D₂ protects neonatal mouse brain from hypoxic ischemic injury. *Journal of Neuroscience* **27** 4303–4312. (doi:10.1523/JNEUROSCI.0321-07.2007)
- Tokugawa Y, Kunishige I, Kubota Y, Shimoya K, Nobunaga T, Kimura T, Saji F, Murata Y, Eguchi N, Oda H *et al.* 1998 Lipocalin-type prostaglandin D synthase in human male reproductive organs and seminal plasma. *Biology of Reproduction* **58** 600–607. (doi:10.1095/biolreprod58.2.600)
- Tootle TL 2013 Genetic insights into the *in vivo* functions of prostaglandin signaling. *International Journal of Biochemistry & Cell Biology* **45** 1629–1632. (doi:10.1016/j.biocel.2013.05.008)
- Toppari J, Larsen JC, Christiansen P, Giwerzman A, Grandjean P, Guillelte LJ Jr, Jegou B, Jensen TK, Jouannet P, Keiding N *et al.* 1996 Male reproductive health and environmental xenoestrogens. *Environmental Health Perspectives* **104** (Suppl 4) 741–803. (doi:10.1289/ehp.96104s4741)
- Ueno N, Takegoshi Y, Kamei D, Kudo I & Murakami M 2005 Coupling between cyclooxygenases and terminal prostanoid synthases. *Biochemical and Biophysical Research Communications* **338** 70–76. (doi:10.1016/j.bbrc.2005.08.152)
- Urade Y & Eguchi N 2002 Lipocalin-type and hematopoietic prostaglandin D synthases as a novel example of functional convergence. *Prostaglandins & Other Lipid Mediators* **68–69** 375–382.
- Urade Y & Hayaishi O 2000a Prostaglandin D synthase: structure and function. *Vitamins and Hormones* **58** 89–120.
- Urade Y & Hayaishi O 2000b Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. *Biochimica et Biophysica Acta* **1482** 259–271. (doi:10.1016/S0167-4838(00)00161-8)
- Urade Y, Fujimoto N & Hayaishi O 1985 Purification and characterization of rat brain prostaglandin D synthetase. *Journal of Biological Chemistry* **260** 12410–12415.
- Wagner T, Wirth J, Meyer J, Zabel B, Held M, Zimmer J, Pasantes J, Bricarelli FD, Keutel J, Hustert E *et al.* 1994 Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9. *Cell* **79** 1111–1120. (doi:10.1016/0092-8674(94)90041-8)
- Wang X, Dyson MT, Jo Y & Stocco DM 2003 Inhibition of cyclooxygenase-2 activity enhances steroidogenesis and steroidogenic acute regulatory gene expression in MA-10 mouse Leydig cells. *Endocrinology* **144** 3368–3375. (doi:10.1210/en.2002-0081)
- Welter H, Kohn FM & Mayerhofer A 2011 Mast cells in human testicular biopsies from patients with mixed atrophy: increased numbers, heterogeneity, and expression of cyclooxygenase 2 and prostaglandin D₂ synthase. *Fertility and Sterility* **96** 309–313. (doi:10.1016/j.fertnstert.2011.05.035)
- Welter H, Kampfer C, Lauf S, Feil R, Schwarzer JU, Kohn FM & Mayerhofer A 2013 Partial loss of contractile marker proteins in human testicular peritubular cells in infertility patients. *Andrology* **1** 318–324. (doi:10.1111/j.2047-2927.2012.00030.x)
- Western PS, Miles DC, van den Bergen JA, Burton M & Sinclair AH 2008 Dynamic regulation of mitotic arrest in fetal male germ cells. *Stem Cells* **26** 339–347. (doi:10.1634/stemcells.2007-0622)
- Western PS, van den Bergen JA, Miles DC & Sinclair AH 2010 Male fetal germ cell differentiation involves complex repression of the regulatory network controlling pluripotency. *FASEB Journal* **24** 3026–3035. (doi:10.1096/fj.09-151555)
- Wilhelm D, Martinson F, Bradford S, Wilson MJ, Combes AN, Beverdam A, Bowles J, Mizusaki H & Koopman P 2005 Sertoli cell differentiation is induced both cell-autonomously and through prostaglandin signaling during mammalian sex determination. *Developmental Biology* **287** 111–124. (doi:10.1016/j.ydbio.2005.08.039)
- Wilhelm D, Hiramatsu R, Mizusaki H, Widjaja L, Combes AN, Kanai Y & Koopman P 2007 SOX9 regulates prostaglandin D synthase gene transcription *in vivo* to ensure testis development. *Journal of Biological Chemistry* **282** 10553–10560. (doi:10.1074/jbc.M609578200)
- Woodward DF, Jones RL & Narumiya S 2011 International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. *Pharmacological Reviews* **63** 471–538. (doi:10.1124/pr.110.003517)
- Wu CC, Shyu RY, Wang CH, Tsai TC, Wang LK, Chen ML, Jiang SY & Tsai FM 2012 Involvement of the prostaglandin D₂ signal pathway in retinoid-inducible gene 1 (RIG1)-mediated suppression of cell invasion in testis cancer cells. *Biochimica et Biophysica Acta* **1823** 2227–2236. (doi:10.1016/j.bbamcr.2012.08.013)

Received 29 July 2014

First decision 21 August 2014

Revised manuscript received 8 September 2014

Accepted 30 September 2014